Stock AKBA AKEBIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
1.34 USD +0.75% Intraday chart for Akebia Therapeutics, Inc. -1.47% +8.06%
23/04 Averoa Seeks EU Approval for Chronic Kidney Disease Drug MT
16/04 Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
PR
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
PR
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Akebia Secures $55 Million Term Loan Financing
PR
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
PR
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
AQ
Akebia Therapeutics: Q3 Earnings Snapshot
AQ
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
PR
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AKBA Stock
  4. News Akebia Therapeutics, Inc.
  5. Press Releases